6
Views
3
CrossRef citations to date
0
Altmetric
Original Article

Lymphocyte Migration Patterns in Autoimmune MRL-lpr/lpr Mice: Relationship to Age, Disease Manifestations and Lymphocyte Homing Receptor Expression

, , , , &
Pages 5-15 | Received 19 Aug 1987, Accepted 20 Oct 1987, Published online: 07 Jul 2009
 

Abstract

We have previously reported that lymphoid cells from systemic lupus erythematosus (SLE) mice with established disease migrate aberrantly.1 This study evaluates the abnormal lymphocyte migration patterns found in MRL-lpr/lpr (MRL/1) mice in relation to age, disease manifestations and the expression of lymphocyte homing receptors, 51chromium-labelled lymph node cells from MRL/1 and from normal histocompatible CBA mice of different ages were injected i.v. into age and sex-matched CBA recipients. Diminished lymph node and increased hepatic uptake of MRL/1 compared to CBA cells was evident as early as 6 weeks of age. Abnormalities in lymphocyte migration antedated the appearance of elevated antihistone antibody (AHA) levels but not the development of lymphadenopathy. Using the monoclonal antibody MEL-14, no differences in the expression of lymphocyte homing receptors between MRL/1 and CBA lymph node cells were found at any age. Thus abnormalities in lymphocyte migration in MRL/1 mice appear as early as six weeks and are not related to changes in homing receptor expression.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.